Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "LA"

8960 News Found

Samsung Epis launches new biotech subsidiary Epis NexLab
Biotech | November 12, 2025

Samsung Epis launches new biotech subsidiary Epis NexLab

The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms


Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics
R&D | November 12, 2025

Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics

The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line


Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Policy | November 11, 2025

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans


Nitinotes secures CE mark for automated suturing platform ‘EndoZip’
Digitisation | November 11, 2025

Nitinotes secures CE mark for automated suturing platform ‘EndoZip’

Enabling a new era in minimally invasive obesity treatment across Europe


SOUKYA launches Rs. 125 crore, 100-bed AYUSH hospital in Bengaluru
Hospitals | November 10, 2025

SOUKYA launches Rs. 125 crore, 100-bed AYUSH hospital in Bengaluru

The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare


Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies
Biotech | November 10, 2025

Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies

The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies


Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Clinical Trials | November 10, 2025

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026


Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
News | November 09, 2025

Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025


Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr
News | November 09, 2025

Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr

Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025